and competently interpreting WHO’s international guidelines on health research.

“In the absence of such committees, it becomes difficult for countries to uphold and enforce research ethics, either for their home researchers or outsiders,” said Leke. “This forum will ensure that African countries establish competent ethic committees capable of facing the challenges of our times”. She added that health researchers needed rigorous and continuous training on the ethical issues they were likely to encounter in the course of their work.

For example, most African women would seek consent from their husbands before submitting to being subjects of any kind of research. “This is something researchers ought to know. In such circumstances, they should beware of coercion to obtain information,” said Leke.

Other members of the steering committee of AfHR include Dr Mutuma Mugambi (Secretary), Dr Sama Martyn (Vice Chairman) and the head of the Essential National Health Research, Cameroon, and Dr Andrew Kitua, the Director-General, National Institutes of Medical Research, United Republic of Tanzania.

James Njoroge, Arusha

In South Africa HIV infection is decreasing, safe sex increasing

South Africans have made substantial changes to their sexual behaviour and fewer people are living with HIV than was previously estimated, according to results from the biggest household HIV/AIDS study ever undertaken in the country.

The independent study was commissioned by former president Nelson Mandela, and is based on a representative sample of almost 10,000 people, 8,840 of whom consented to anonymous HIV saliva tests.

An estimated 4.5 million people — 11.4% of the population over the age of two — are HIV-positive, which is lower than the government’s estimate of 4.75 million people, and much lower than UNAIDS estimates based on data from antenatal clinics.

The latest UNAIDS fact sheets do note a decline, however, reporting that for pregnant women under 20, [South Africa’s] HIV prevalence rates fell to 15% in 2001 (down from 21% in 1998). This, along with the drop in syphilis rates among pregnant women attending antenatal clinics (down to 2.8% in 2001, from 11% four years earlier) suggests that awareness campaigns and prevention programmes are bearing fruit.

A major challenge now is to sustain and build on such tentative success.

The Mandela study also found that since a health department survey was made in 1998, many more people have been practising safer sex.

We found that the number of women who had no current sexual partner had increased, and condom use had increased significantly,” said Olive Shisana, principal investigator for the study. “For example, for women aged 15–49, condom use at last sexual intercourse has more than tripled, from 8% in 1998 to 29% in the present study, and amongst women aged 20–24 it has increased from 14% to 47%.”

Young people (aged 15–24) were most likely to use condoms: among those sexually active, 57% of males and 46% of females had used a condom the last time they had sex. Over 90% of youths and adults also said that they could get a condom if they needed one — mostly through the Department of Health’s free condom programme at public clinics and hospitals.

Among 15–24-year-olds only 56% of males and 58% of females had previously had sex, and there were very low levels of partner turnover. Of those who were sexually active, 85% reported that they had had only one partner in the past year. For adults aged 25–49, the rate was 93%.

Nearly half of all males and over a third of females over 15 years of age reported that they had changed their behaviour as a result of HIV/AIDS. Steps taken included staying faithful to one partner, condom use, sexual abstinence and reducing the number of sexual partners. The survey found that African women aged 25–29 who lived in informal settlements were most at risk of HIV infection, but it also clearly showed that everyone could be affected.

The infection rate among whites was unexpectedly high, at 6.2%. This is considerably higher than in countries with predominantly white populations such as the US, Australia and France, where prevalence amongst whites is less than 1%. HIV prevalence amongst Africans was highest (12.9%). This can be explained by historical factors, such as labour migration and relocation.

In addition, more African people live in informal settlements, which had the highest HIV prevalence of all household types (21.3%). Coloured (mixed race) prevalence was 6.1% and among Indians 1.6%.

Prevalence among children aged 2–14 years was unexpectedly high at 5.6%. Shisana said more research was needed to determine the causes of this, though sexual abuse and unsafe injections could be among them.

Females accounted for 12.8% of those testing HIV-positive, and males 9.5%. Among those aged 15–24, 12% of females and 6% of males tested positive.

At a briefing to release the report, Mr Mandela appealed for prevention efforts to be increased. “What is important is what we do on the ground to ensure that people understand how HIV is contracted and how to deal with it,” he said. “We have to smash the perception that if you enter a house where people have AIDS, you will contract the virus,” he added.

Kerry Cullinan, Durban

Drug companies should cut prices for developing countries, says G8 report

Key pharmaceuticals should be sold to developing countries at much lower prices than they command in the richer parts of the world, says a British-led report on global access to medicines.

The report of the UK Working Group on Increasing Access to Essential Medicines in the Developing World, chaired by Britain’s International Development Secretary, Clare Short, was commissioned by the G8 group of the world’s richest countries, and involved UK drugs companies as well as developing countries in the lengthy negotiations leading to its publication.

The companies involved have effectively “signed up” to its conclusions, but US companies, which dominate the world market in Pharmaceuticals, were notable absentees.

The report should now go before the next G8 summit in France in June, if the French Government, which will chair the meeting, agrees to put it on the agenda. Its reception by the
assembled governments will then decide the future of its proposals.

Tony Blair, the British Prime Minister, discussed the report at 10 Downing Street, London, last November, at a working breakfast with WHO’s Director-General, Dr Gro Harlem Brundtland; the Ugandan High Commissioner, Professor George Kirya; Chris Viehbacher of GlaxoSmithKline; other pharmaceutical industry leaders; and representatives of the European Commission and charitable foundations.

Although Clare Short’s spokeswoman described the breakfast as “private”, it is clear that the main issue was how to implement the report’s recommendations. According to the report itself, while Europe is more or less on board, the US position is less clear. “The European Commission has laid much of the groundwork for this agenda in Europe through their Plan for Action,” the report states, “resulting in a European Parliament Resolution. Further work will need to be done to secure the commitment of European governments and industry to work in partnership on this agenda. Working with the US Government and gaining their support will be particularly critical given the importance and size of the US Industry. Continued dialogue directly with US Industry may be a promising way forward. There may be scope for tabling this agenda through regional and global industry associations”.

According to Dr Brundtland, improving access to medicines will not be easy. “It is a complex struggle where governments, a range of actors in the private sector, and civil society all play important roles”.

On the company side, John Patterson of AstraZeneca, commented: “This is a many-faceted challenge and needs the best efforts of all of us, in partnership, to make an impact. Companies are committed to making their contribution ... by providing more and better medicines so that they can be accessed more easily by patients in the developing world, without undermining the ability of industry to operate in the developed world.”

Chris Viehbacher said “GlaxoSmithKline welcomes this Report.” He claimed that his company already offered “sustainable, not-for-profit preferential prices for our antiretrovirals and antimalarials to a wide range of customers in all the least developed countries and all of sub-Saharan Africa — a total of 63 countries”. But increasing the scope of preferential pricing “requires a sustainable framework, incorporating ... barriers against diversion of product. [This report] is a very useful step towards meeting these needs.”

The full report is available from: URL: www.dfid.gov.uk/Pubs/files/access_to_medicines_report28.11.pdf

Robert Walgate, Bulletin

**Vaccine against cervical cancer passes “proof of principle”**

A recombinant vaccine against the human sexually-transmitted papilloma-virus type HPV-16, which is thought to cause as many as half of all cervical cancers, has been shown to prevent long-term HPV-16 infections in a trial with 2400 young women.

This Merck vaccine is the first of what may be several candidates for a vaccine against HPV infections, some prophylactic and some therapeutic, but it has come through with flying colours. Although the trial was designed to measure HPV infection and not cancer, which occurs with only a small percentage of infections, it may prove significant that nine women in the placebo (unvaccinated) group developed clinical lesions — the beginning of cancer — but none did so in the vaccinated group (New England Journal of Medicine 2002;347:1645-51).

Sonia Pagliusi of the WHO Initiative for Vaccine Research told the Bulletin “This is a very interesting vaccine for developing countries as they have 80% of the world’s cervical cancer. And they have few other options. They can do the Pap [smear test, requiring cytological observations] but it’s not very effective — it’s not working. People take the test, but follow-up is difficult”.

According to Andreas Ulrich, who works on national cancer control planning issues at WHO, “Cervical cancer is a high priority: it’s first or second in developing countries, among all cancers.”

Pagliusi added: “This is the first proof of principle of an HPV vaccine in humans. But it is important to know if the result is relevant to the disease”. So it will be necessary to do larger trials measuring the effect of the vaccine on pre-cancerous lesions. “HPV is not like HIV — it’s only a small percentage of infections that go on to cause cancer.”

Moreover, there are 15 high-risk HPV viruses. Type 16 causes 50% of cases of cervical cancer. Type 18 causes an additional 10–15%; then Types 31, 33, 45 and others account for another 5% or so. An ideal vaccine should cover several virus types. “But the object of this trial was a proof of principle, which would be more difficult to show with the other viruses because they are relatively rare. You’d need even bigger trials to get a statistical result” said Pagliusi.

Vaccines are the most cost-effective interventions to prevent life-threatening infections “And we hope we will need to vaccinate only once in a woman’s lifetime, before they become sexually active — with a three-shot course like HepB” said Pagliusi.

The Merck HPV vaccine is based on the same principle as HepB: a recombinant capsid protein. The trial has so far only measured protection for 1.5 years. But it is a great beginning.

Robert Walgate, Bulletin

**Peru tries vinegar against cervical cancer**

Women in the isolated Amazon jungle region of San Martin in Peru are participating in a research programme to prevent cervical cancer, which kills an unusually large number of women in that country — some 40 per 100,000 women per year compared to just over 9 per 100,000 per year in North America, according to figures from WHO’s International Agency for Research on Cancer.

Under the programme the women in San Martin, many of them small farmers who live far from the nearest health post, are being diagnosed and treated for pre-cancerous lesions in one visit, rather than having to return at a later time to learn the results of the usual Pap smear test. Before the programme began, only 23% of the women with abnormal Pap smear tests had received follow-up treatment in San Martin, according to a survey done before the screening and treatment programme began.

The programme is sponsored by the Pan American Health Organization and the national and departmental health